Boehringer Ingelheim

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. The company researches FOXO proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Saiba Animal Health is a biotechnology company dedicated to developing innovative therapeutic drugs and vaccines aimed at treating chronic diseases in dogs. The firm utilizes a recombinant virus-like particle vaccine platform designed to induce long-lasting antibodies that specifically target key molecules associated with various chronic conditions. By focusing on the treatment of allergies, inflammation, pain, nervous system disorders, and cancer, Saiba Animal Health aims to enhance the well-being and quality of life for both pets and their owners.

Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA.

Shengbao Bio is committed to the development of novel live bacterial medications, leveraging gene circuits and precise regulation of gene and payload expression.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

Asgard Therapeutics is a private biotech company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Emerging as a spin-off from Lund University, the company utilizes its proprietary TrojanDC technology to initiate immune responses by leveraging the unique properties of professional antigen-presenting cells. This approach aims to create efficient and personalized gene therapy products that activate robust anti-cancer immune defenses. By offering off-the-shelf solutions, Asgard Therapeutics seeks to provide new treatment options for patients suffering from cancers that are resistant to traditional therapies, thereby expanding the possibilities for effective cancer treatment.

Ilara Health, founded in 2018 and headquartered in Nairobi, Kenya, focuses on enhancing healthcare access in rural Africa by developing and distributing AI-powered diagnostic devices. These compact devices are designed for primary care doctors in peri-urban and rural clinics, providing accurate and affordable diagnostic services. Ilara Health integrates its technology within a proprietary platform that connects to an electronic medical record system, allowing healthcare providers to efficiently record and manage patient data. By leveraging existing healthcare infrastructure, Ilara Health aims to improve the accessibility and affordability of diagnostic services in underserved regions.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer. Recognizing the ongoing need for novel treatments despite advancements in classical therapies, T3 Pharmaceuticals aims to enhance the lives of cancer patients by developing highly specific and efficient immuno-oncology therapies. Their proprietary approach utilizes a bacterial type III secretion system to deliver therapeutic proteins directly to solid tumors, providing a potential breakthrough in cancer treatment.

Glox Therapeutics is a company that is pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins.

Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.

TeleVet, Inc. operates a mobile application designed to facilitate remote communication between pet owners and veterinarians. The application enables users to schedule virtual consultations, book follow-up appointments, and receive care through text, call, and video chat. It also supports veterinarians by providing tools for appointment scheduling, telemedicine services, and digital prescriptions, integrating seamlessly with existing veterinary practice management systems. Additionally, the app offers automated communication features, such as email templates and social media posts, to enhance client engagement regarding pet health services. Founded in 2015 and based in Austin, Texas, TeleVet, Inc. was previously known as Horse Facts, Inc. before rebranding in January 2016. The application is available for download on both the App Store and Google Play.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

C-mo Medical Solutions specializes in developing monitoring devices aimed at providing a comprehensive assessment of cough patterns in patients. The company's portable and ergonomic wearables facilitate long monitoring periods and the detection of distinctive cough patterns. With fully automated analysis capabilities, these devices enable healthcare professionals to deliver accurate diagnoses and prescribe personalized treatment plans. By addressing key use-cases throughout the patient management lifecycle, C-mo Medical Solutions plays a significant role in enhancing cough-related healthcare.

Trutino Biosciences is a biopharmaceutical company focused on developing innovative cytokine therapies for cancer treatment. Established in 2017 and based in San Diego, California, the company utilizes its proprietary On-Demand-Cytokine (ODC) platform technology to create therapeutic candidates that can be administered in an inactive form and activated locally at the tumor site. This approach aims to minimize the severe toxicity associated with traditional cytokine therapies while enhancing their efficacy, whether used alone or in combination with other treatments. Trutino's work in immuno-oncology seeks to stimulate tumor-specific immune cells to selectively destroy targeted cancer cells, thereby optimizing treatment responses for patients.

ArrePath is a company focused on discovering anti-infective drugs to tackle the global issue of drug-resistant infections. It operates a drug discovery platform that aims to develop therapies specifically targeting antimicrobial resistance. The platform is designed to create new medicines that address multiple targets within disease pathways, which may enhance treatment efficacy while minimizing risks during the discovery and development phases. This approach supports healthcare professionals in treating chronic infections and improving patient recovery times.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Asgard Therapeutics is a private biotech company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Emerging as a spin-off from Lund University, the company utilizes its proprietary TrojanDC technology to initiate immune responses by leveraging the unique properties of professional antigen-presenting cells. This approach aims to create efficient and personalized gene therapy products that activate robust anti-cancer immune defenses. By offering off-the-shelf solutions, Asgard Therapeutics seeks to provide new treatment options for patients suffering from cancers that are resistant to traditional therapies, thereby expanding the possibilities for effective cancer treatment.

Optina Diagnostics Inc. is a diagnostics company based in Montréal, Canada, founded in 2010. It specializes in the early detection of Alzheimer's disease through innovative hyperspectral imaging technology that examines the retina. By employing non-invasive diagnostic tests, Optina Diagnostics identifies key biomarkers, such as beta-amyloid plaques, which are crucial for assessing patients' health and disease risk. The company's advanced imaging systems also aid in the detection of age-related macular degeneration and ocular diabetic retinopathy, providing physicians with critical information that enables timely and appropriate patient care. Through its focus on retinal features and artificial intelligence, Optina Diagnostics aims to transform the assessment of brain health and address under-diagnosed diseases.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on developing innovative immuno-oncology therapeutics. Founded in 2019, the company specializes in arenavirus-based drug candidates aimed at stimulating immune responses to target primary tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's approach involves reprogramming the immune system to effectively identify and eliminate malignant tumor tissue, thereby offering potential new treatment options for cancer. Through its novel immuno-virotherapy, Abalos Therapeutics seeks to harness the full capabilities of the immune system specifically against cancer cells.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, focuses on developing a digital therapeutic for myopia, or shortsightedness, a common visual condition affecting around one in three individuals globally. The company aims to create a clinically validated therapy to slow the progression of myopia in children and adolescents. Its innovative technology employs light stimulation targeting specific photosensitive cells in the retina, which modulates dopamine levels—a neurotransmitter that plays a crucial role in eye growth regulation. This digital therapeutic can be seamlessly integrated with smartphone use, making it an accessible solution for health professionals treating myopia. Dopavision is also supported by the German government through the "Industrie-in-Klinik" program, receiving €1.4 million over three years to advance its research and development efforts.

xCures, Inc. is a company focused on transforming cancer treatment through its innovative AI-based precision oncology platform, established in 2018 and headquartered in Los Altos, California. The platform addresses the limitations of traditional drug-centric approaches by integrating cancer research with patient care. It operates as a perpetual trial, continuously collecting Real World Evidence (RWE) to enhance decision-making in treatment recommendations for advanced cancer patients. By utilizing machine learning, xCures structures insights from tumor boards and matches patients with the most effective treatment options based on their individual cases. This approach not only streamlines the process for healthcare providers but also reduces the time and cost associated with drug development, ultimately aiming to improve patient outcomes and save lives.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in patients with cardiovascular diseases. The firm specifically targets genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor aims to provide innovative solutions that enable healthcare professionals to effectively treat these conditions and improve heart health in affected individuals.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies to treat hearing loss. Founded in 2018, the company specializes in advanced stem cell technology that aims to repair damaged or dead sensory cells in the inner ear, specifically targeting sensorineural hearing loss. By restoring the cytoarchitecture of the inner ear, Rinri Therapeutics seeks to enable medical professionals to effectively restore hearing for affected patients.

Delonix Bioworks Ltd. specializes in synthetic biology, focusing on the development of innovative medicines and vaccination technologies. The company designs and engineers microbial strains to create treatments for infectious diseases, cancer, and other health challenges. By enhancing traditional vaccine research, Delonix Bioworks aims to address antimicrobial-resistant infections, providing healthcare providers with more effective solutions for patient care. Through its commitment to rational and scientific design, the company seeks to advance the field of medicine and improve treatment outcomes.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

NBE-Therapeutics GmbH, founded in 2012 and based in Basel, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for cancer treatment. The company is focused on creating innovative therapies that aim to enhance survival rates and improve the quality of life for cancer patients globally. Utilizing a proprietary ADC platform, NBE-Therapeutics develops immune-stimulatory therapies that combine potent anthracycline payloads with targeted delivery to tumor cells. This approach not only aims to directly attack cancer cells but also to elicit a durable immunological response against tumors, positioning the company as a significant player in the biopharmaceutical industry dedicated to cancer care.

Labor Dr. Merk & Kollegen GmbH, established in 1971, specializes in high-quality diagnostics and laboratory services for the pharmaceutical industry and medical device manufacturers. The company has developed significant expertise in biotechnology, virology, microbiology, and toxicology, offering contract manufacturing, biosafety testing, and process development. They provide a comprehensive range of Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) compliant methods for preclinical studies and quality control of final products, particularly in virological and microbiological testing. The experienced team at Labor Dr. Merk & Kollegen ensures personalized consultation throughout study design and test performance, delivering reliable and economical solutions tailored to their clients' needs.

Perfood GmbH, founded in 2017 and based in Lübeck, Germany, specializes in digital therapies that focus on personalized nutrition. The company develops digital therapeutic solutions aimed at weight management and migraine prevention. By utilizing sensors, lab results, and comprehensive analyses, Perfood identifies individualized actions to combat diseases, offering an effective alternative to traditional medications without the associated side effects. Their approach incorporates proprietary datasets and algorithms to create engaging and accessible dietary adjustments, emphasizing low-glycemic diets tailored to individual needs. This innovative methodology not only addresses the root causes of health issues but also enhances the user experience in managing their well-being.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator, which covers pet healthcare, foster care, bathing, SPA, beauty, food, entertainment and leisure services.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019. The company is dedicated to developing innovative disease-modifying therapeutics aimed at restoring cellular balance in patients suffering from neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. Libra Therapeutics focuses on small molecule drugs that enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Through its distinct molecular approaches, the company aims to address the cellular imbalances that characterize these debilitating conditions, thereby providing potential new treatment options for affected individuals.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.

Bodyport Inc. is a company based in San Francisco, California, that specializes in the development of sensor-equipped weighing scales designed specifically for cardiac patients. The company's flagship offering is a biomarker-driven virtual clinic aimed at the prevention and management of heart disease. Utilizing proprietary sensor technology, Bodyport's device measures critical health metrics such as blood pressure, heart rate, heart rate variability, and arterial stiffness through the feet. This data helps healthcare providers assess patients' overall health and identify early signs of cardiovascular disease, facilitating timely interventions to prevent hospitalizations and enhance quality of life. In addition to its hardware, Bodyport offers an online patient portal and educational resources to support users in managing their health. The company was incorporated in 2015.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Proxygen is a biotechnology company focused on developing innovative therapies for cancer and other life-threatening diseases. The company utilizes molecular glue degraders, a novel approach that targets and eliminates disease-causing proteins by reprogramming the natural protein recycling mechanisms within cells. This method offers a new strategy for treating incurable diseases, moving beyond traditional inhibition of harmful proteins. Proxygen is also advancing the druggable target space through the creation of rational discovery assays, which facilitate the identification and development of novel glue degraders at scale. This positions the company as a leader in exploring this previously uncharted area of chemical space.

Global Stem Cell Technology is a veterinary biotech company specializing in the development and production of advanced stem cell products for horses and dogs. The company focuses on blood-derived mesenchymal stem cells, which are intended for clinical applications in animals. By translating regenerative medicine into practical treatments, Global Stem Cell Technology aims to enhance animal welfare and improve the quality of care available for these animals.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer. Recognizing the ongoing need for novel treatments despite advancements in classical therapies, T3 Pharmaceuticals aims to enhance the lives of cancer patients by developing highly specific and efficient immuno-oncology therapies. Their proprietary approach utilizes a bacterial type III secretion system to deliver therapeutic proteins directly to solid tumors, providing a potential breakthrough in cancer treatment.

DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

Northern Biologics Inc. is an early-stage biologics company based in Toronto, Canada, focused on developing antibody-based therapeutics for oncology and fibrosis. Founded in 2014, the company employs advanced antibody discovery techniques, specifically utilizing a phage display platform developed by top researchers at the University of Toronto. Northern Biologics aims to create therapeutic antibodies that modify the tumor microenvironment and act as functional modulators of key signaling pathways related to cancer and fibrosis. The company's innovative approach is designed to enable personalized treatment options for patients. In 2020, Northern Biologics became a subsidiary of Boehringer Ingelheim International GmbH and maintains a strategic collaboration with Celgene Corporation.

Wellth is a digital health company based in New York that aims to enhance treatment adherence among individuals with chronic conditions. By leveraging behavioral economics, Wellth addresses the barriers that hinder patients from forming healthy habits and effectively managing their diseases. The company operates a mobile application that provides targeted incentive plans, reminders, and information to motivate users to engage in preventive health behaviors. Its platform not only empowers consumers to improve their adherence to medication and care plans but also helps reduce preventable hospitalizations and healthcare costs. Wellth's approach includes proven outcomes demonstrated through randomized controlled trials, making it a valuable solution for insurers and healthcare providers seeking to improve population health. Through its user-friendly application, Wellth supports members in establishing sustainable healthy habits while generating cost savings for payors.

Actym Therapeutics is a biotechnology company based in Berkeley, California, dedicated to developing innovative immuno-oncology therapies for cancer treatment. Founded in 2017, the company has created a unique therapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy), which uses an attenuated microbial approach to target solid tumors while sparing healthy tissue. This platform allows for the delivery of multiple immuno-modulatory payloads directly to immune cells residing within tumors, addressing challenges faced by traditional therapies. In preclinical studies, STACT has shown promise in enhancing treatment efficacy by engaging various biological pathways from a single therapy. The company successfully secured $34 million in a Series A financing round in April 2020, which was co-led by prominent venture funds, highlighting its potential in the biopharmaceutical landscape.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

NBE-Therapeutics GmbH, founded in 2012 and based in Basel, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for cancer treatment. The company is focused on creating innovative therapies that aim to enhance survival rates and improve the quality of life for cancer patients globally. Utilizing a proprietary ADC platform, NBE-Therapeutics develops immune-stimulatory therapies that combine potent anthracycline payloads with targeted delivery to tumor cells. This approach not only aims to directly attack cancer cells but also to elicit a durable immunological response against tumors, positioning the company as a significant player in the biopharmaceutical industry dedicated to cancer care.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on developing innovative immuno-oncology therapeutics. Founded in 2019, the company specializes in arenavirus-based drug candidates aimed at stimulating immune responses to target primary tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's approach involves reprogramming the immune system to effectively identify and eliminate malignant tumor tissue, thereby offering potential new treatment options for cancer. Through its novel immuno-virotherapy, Abalos Therapeutics seeks to harness the full capabilities of the immune system specifically against cancer cells.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer. Recognizing the ongoing need for novel treatments despite advancements in classical therapies, T3 Pharmaceuticals aims to enhance the lives of cancer patients by developing highly specific and efficient immuno-oncology therapies. Their proprietary approach utilizes a bacterial type III secretion system to deliver therapeutic proteins directly to solid tumors, providing a potential breakthrough in cancer treatment.

Tacalyx GmbH is an oncology company based in Berlin, Germany, specializing in the discovery and development of Tumor-Associated Carbohydrate Antigens (TACAs) as innovative targets for cancer therapy. Originating as a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Tacalyx leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures are essential for generating and identifying antibodies aimed at developing new therapeutics. TACAs are characterized by their specific expression in tumors, which arises from abnormal glycosylation and is associated with promoting metastasis, angiogenesis, and immune system suppression. By combining sophisticated synthesis capabilities with comprehensive analysis and screening, Tacalyx aims to create novel immunotherapies that effectively stimulate anti-cancer responses.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, focuses on developing a digital therapeutic for myopia, or shortsightedness, a common visual condition affecting around one in three individuals globally. The company aims to create a clinically validated therapy to slow the progression of myopia in children and adolescents. Its innovative technology employs light stimulation targeting specific photosensitive cells in the retina, which modulates dopamine levels—a neurotransmitter that plays a crucial role in eye growth regulation. This digital therapeutic can be seamlessly integrated with smartphone use, making it an accessible solution for health professionals treating myopia. Dopavision is also supported by the German government through the "Industrie-in-Klinik" program, receiving €1.4 million over three years to advance its research and development efforts.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies to treat hearing loss. Founded in 2018, the company specializes in advanced stem cell technology that aims to repair damaged or dead sensory cells in the inner ear, specifically targeting sensorineural hearing loss. By restoring the cytoarchitecture of the inner ear, Rinri Therapeutics seeks to enable medical professionals to effectively restore hearing for affected patients.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.

Wellth is a digital health company based in New York that aims to enhance treatment adherence among individuals with chronic conditions. By leveraging behavioral economics, Wellth addresses the barriers that hinder patients from forming healthy habits and effectively managing their diseases. The company operates a mobile application that provides targeted incentive plans, reminders, and information to motivate users to engage in preventive health behaviors. Its platform not only empowers consumers to improve their adherence to medication and care plans but also helps reduce preventable hospitalizations and healthcare costs. Wellth's approach includes proven outcomes demonstrated through randomized controlled trials, making it a valuable solution for insurers and healthcare providers seeking to improve population health. Through its user-friendly application, Wellth supports members in establishing sustainable healthy habits while generating cost savings for payors.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

NBE-Therapeutics GmbH, founded in 2012 and based in Basel, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for cancer treatment. The company is focused on creating innovative therapies that aim to enhance survival rates and improve the quality of life for cancer patients globally. Utilizing a proprietary ADC platform, NBE-Therapeutics develops immune-stimulatory therapies that combine potent anthracycline payloads with targeted delivery to tumor cells. This approach not only aims to directly attack cancer cells but also to elicit a durable immunological response against tumors, positioning the company as a significant player in the biopharmaceutical industry dedicated to cancer care.

Acousia Therapeutics GmbH is a biotech company based in Tübingen, Germany, founded in 2012. It focuses on developing small molecule drugs aimed at treating hearing loss through local application. The company's innovative approach targets the regeneration of sensory hair cells in the inner ear, which are essential for hearing. By stimulating cellular regeneration from supporting cells, Acousia's therapies aim to restore hearing in patients affected by various conditions, including noise trauma, ototoxic drug treatment, and sudden deafness. Additionally, its research and development efforts are directed towards addressing age-related hearing decline.

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Aelin Therapeutics is a Belgian biotherapeutics company established in 2017 and headquartered in Heverlee. It specializes in developing innovative antibiotics and therapeutics through its proprietary Pept-in technology, which utilizes protein aggregation to achieve functional knockdown of target proteins. This platform is designed to address challenging medical conditions, including infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. The company was founded by VIB in collaboration with partner universities, including KU Leuven, VUB, and UGent, and is backed by extensive preclinical proof-of-concept data. Aelin Therapeutics' approach allows for the rational design of novel biotherapeutics, distinguishing itself from traditional therapeutic modalities by targeting intracellular spaces typically inaccessible to small molecules or antibodies. The technology's versatility extends beyond human applications, demonstrating efficacy against bacteria, cancer cells, fungi, viruses, and even plant cells.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Sentien Biotechnologies, Inc. is a clinical-stage company focused on developing innovative cell therapies aimed at restoring immune system balance and enhancing treatment options for patients with systemic inflammatory diseases. Founded in 2008, the company is headquartered in Medford, Massachusetts. Its flagship product, SBI-101, utilizes a novel blood conditioning approach that immobilizes Mesenchymal Stromal Cells (MSCs) in an extracorporeal device, allowing for sustained and controlled release of anti-inflammatory and regenerative molecules. This method significantly enhances the therapeutic activity of MSCs compared to traditional delivery methods like direct injection or intravenous infusion. Sentien Biotechnologies also offers the Sentinel device, which supplements patient blood with MSC-derived secretions during dialysis, addressing immune dysfunction in acute renal failure and promoting tissue repair.

Sentieon, Inc. is a biotechnology company founded in 2014 and headquartered in Mountain View, California, specializing in cloud-based bioinformatics solutions for the life sciences and clinical markets. The company develops a suite of bioinformatics tools designed for the efficient processing of genomics data, focusing on high accuracy and computational efficiency. Key products include Sentieon DNAseq, which facilitates germline DNA analysis, and Sentieon TNseq, used for detecting somatic variants in tumor-normal samples. Sentieon's software solutions are characterized by their scalability, deployability, and upgradability, allowing them to adapt to various user needs. The company's advanced algorithms and robust software implementation ensure rapid turnaround times and consistent results, benefiting scientists, clinicians, and patients by enhancing precision in genomic data analysis.

Merial Limited is an animal healthcare company specializing in the research, development, and production of pharmaceutical products and vaccines for livestock, pets, and wildlife. The company offers a range of products in various medical fields, including anaesthetic, antiparasitic, antimicrobial, gastrointestinal, respiratory, and cardiovascular medicines. Notable products include IVOMEC for treating parasites in cattle, sheep, and swine, and FRONTLINE for pets. Merial's vaccines address significant diseases affecting animals, such as Newcastle Disease and Avian Flu. The company serves a diverse clientele, including veterinarians, pet owners, farmers, and food animal producers globally. Founded in 1997 as a joint venture between the animal health divisions of Rhône-Poulenc and Merck, Merial is headquartered in Duluth, Georgia, and operates in multiple countries worldwide. It is a subsidiary of Sanofi-Aventis, which acquired Rhône-Poulenc and later took over Merck's stake in the company.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

Acousia Therapeutics GmbH is a biotech company based in Tübingen, Germany, founded in 2012. It focuses on developing small molecule drugs aimed at treating hearing loss through local application. The company's innovative approach targets the regeneration of sensory hair cells in the inner ear, which are essential for hearing. By stimulating cellular regeneration from supporting cells, Acousia's therapies aim to restore hearing in patients affected by various conditions, including noise trauma, ototoxic drug treatment, and sudden deafness. Additionally, its research and development efforts are directed towards addressing age-related hearing decline.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

NBE-Therapeutics GmbH, founded in 2012 and based in Basel, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for cancer treatment. The company is focused on creating innovative therapies that aim to enhance survival rates and improve the quality of life for cancer patients globally. Utilizing a proprietary ADC platform, NBE-Therapeutics develops immune-stimulatory therapies that combine potent anthracycline payloads with targeted delivery to tumor cells. This approach not only aims to directly attack cancer cells but also to elicit a durable immunological response against tumors, positioning the company as a significant player in the biopharmaceutical industry dedicated to cancer care.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Rigontec GmbH is a biopharmaceutical company specializing in RNA-based immunotherapeutics aimed at treating cancer and viral diseases. Founded in 2014 and based in Planegg, Germany, the company focuses on developing compounds that activate the immune receptor retinoic acid-inducible gene I (RIG-I), specifically through its lead product, ImOl100. This compound acts as a minimal mimic of the naturally occurring 3pRNA motif found in viral RNAs, stimulating the immune response effectively. Rigontec's approach circumvents common challenges faced by traditional cancer therapies, such as vaccines and checkpoint inhibitors, by targeting RIG-I pathways to induce tumor cell death and promote long-term immunity. In 2017, Rigontec became a subsidiary of Merck & Co., Inc., enhancing its capabilities in the field of immuno-oncology.

STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.

Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.